Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | STAT1 | P42224 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18873552 | 0.85 | PDE4D (0.61) | RAB9ANPC1KMT2AAURKASMN1; SMN2 | |
| SCHEMBL1300653 | 0.80 | AURKA (0.53) | RAB9ANPC1KMT2AAURKASMN1; SMN2 | |
| SCHEMBL4105624 | 0.80 | PDE4D (0.67) | KMT2AAURKASMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL2162420 | 0.79 | SMN1; SMN2 (0.52) | RAB9ANPC1KMT2AAURKASMN1; SMN2 | |
| SCHEMBL22548001 | 0.75 | RAB9A (0.72) | RAB9ANPC1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL12108656 | 0.74 | PDE4D (0.50) | RAB9ANPC1KMT2AAURKASMN1; SMN2 | |
| SCHEMBL7512103 | 0.74 | SMN1; SMN2 (0.62) | RAB9ANPC1KMT2AAURKASMN1; SMN2 | |
| SCHEMBL16817619 | 0.73 | SMN1; SMN2 (0.46) | RAB9ANPC1KMT2AAURKASMN1; SMN2 | |
| SCHEMBL31335067 | 0.72 | HCAR2 (0.51) | RAB9ANPC1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL17965761 | 0.72 | TDP1 (0.61) | RAB9ANPC1KMT2ASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| EP-2519664-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | Avila Therapeutics, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | VERNALIS R & D LIMITED (GB) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | RAB9A 3853/4885NPC1 4245/4885KMT2A 1160/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | RAB9A 3853/4885NPC1 4245/4885KMT2A 1160/4885 |
| US-20090131470-A1 | PYRAZOLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | PDK1, CHEK1, PDK3 | RAB9A 1256/4885NPC1 4104/4885KMT2A 859/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | RAB9A 3853/4885NPC1 4245/4885KMT2A 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.